Article

B+L voluntarily recalls eye vitamins

Bausch + Lomb (B+L) is voluntarily recalling an eye vitamin (PreserVision Eye Vitamin AREDS 2 Formula with Omega 3) after receiving ?a small number of reports predominantly within a specific age group, age 70 and older, who reported difficulty swallowing or a choking sensation when taking the soft gel,? according to the company.

Madison, NJ-Bausch + Lomb (B+L) is voluntarily recalling an eye vitamin (PreserVision Eye Vitamin AREDS 2 Formula with Omega 3) after receiving “a small number of reports predominantly within a specific age group, age 70 and older, [that] reported difficulty swallowing or a choking sensation when taking the soft gel,” according to the company.

The formulation, the only supplement being recalled by the company, is only available in the United States.

“To clarify, the formulation . . . is safe,” B+L officials said in a statement. “While many of our customers can comfortably swallow the supplement, we believe the design of the soft gel requires further consideration.”

The company plans to release the vitamin later this year in a smaller soft gel that will be dosed twice per day, two pills per dose.

B+L has notified retailers and eye-care professionals and is asking consumers to return the product to the company even if they find swallowing it comfortable. Consumers can call 800/553-5340 for instructions on returning and reimbursement. The customer service line is open 9 a.m. to 5 p.m. EST Monday through Friday.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.